The Deal
Sunday, November 8, 
5:30 am

For Icahn, Exelixis marks the biotech spot

  Share     E-Mail    Discussion    Print Story
icahn.jpg When Carl Icahn gets involved in biotech companies, action often follows. He sold off ImClone Systems Inc. to Eli Lilly and Co., helped split Enzon Pharmaceuticals in two and unsuccessfully pushed for a sale of Biogen Idec Inc.

Continue reading below

Also on Dealscape

Now he's bought into Exelixis Inc., a high-profile Bay Area firm that has plenty of drugs in its pipeline but nothing on the market. As of Sept. 30, Icahn through his Icahn Capital LP fund, is the proud owner of 1.3 million shares, according to an Securities and Exchange Commission filing released Nov. 14. Exelixis stock closed at $2.98 a share Tuesday.

With or without Icahn, Exelixis is at a crossroads. It ended its six-year development partnership with GlaxoSmithKline plc last month, and the developer of small-molecule cancer drugs says it must move quickly to put some of its pipeline in other people's hands, much like a family that can't afford to raise all its kids. Expect cash-raising deals to follow soon.

After spending $270 million last year and more than $150 million the first half of 2008, the firm needs to trim its sails. Recent layoffs of 78 staffers will help (though don't tell that to those laid off), and the firm says it will outlicense at least one drug to a larger partner before year's end. - Alex Lash



Post a comment





The Deal Pipeline

Deal Video


Inside The Deal: Linklaters' Schmidt says how regulators handled Pfizer Inc.'s acquisition of Wyeth is an outlier of how others merger reviews will be conducted.


More video...

Crisis On Wall Street
Technology
Deals of The Decade

Community

Industry Insight

Dealing with frozen bank lending

If your bank is not willing to lend, what can you do as your company continues to seek growth?


Judgment Call

The coming age of the renminbi

The Chinese currency will play an increasingly important role in international commerce and finance.


Industry Insight

Banking on PE investments

Howls of protest greeted the FDIC policy statement, but the financial services industry should get over it.


footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg


©Copyright 2009, The Deal, LLC. All rights reserved. Please send all technical questions, comments or concerns to the Webmaster.